A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2).

Trial Profile

A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2).

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs AZD 6280; Caffeine; Midazolam
  • Indications Anxiety disorders
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top